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Summary
Background Treatments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, 
but to our knowledge no placebo-controlled trials have assessed visual function preservation, and the observation 
periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients 
given latanoprost compared with those given placebo.
Methods In this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-
angle glaucoma at ten UK centres (tertiary referral centres, teaching hospitals, and district general hospitals). Eligible 
patients were randomly allocated (1:1) with a website-generated randomisation schedule, stratiﬁ ed by centre and with a 
permuted block design, to receive either latanoprost 0·005% (intervention group) or placebo (control group) eye drops. 
Drops were administered from identical bottles, once a day, to both eyes. The primary outcome was time to visual ﬁ eld 
deterioration within 24 months. Analyses were done in all individuals with follow-up data. The Data and Safety Monitoring 
Committee (DSMC) recommended stopping the trial on Jan 6, 2011 (last patient visit July, 2011), after an interim analysis, 
and suggested a change in primary outcome from the diﬀ erence in proportions of patients with incident progression 
between groups to time to visual ﬁ eld deterioration within 24 months. This trial is registered, number ISRCTN96423140.
Findings We enrolled 516 individuals between Dec 1, 2006, and March 16, 2010. Baseline mean intraocular pressure 
was 19·6 mm Hg (SD 4·6) in 258 patients in the latanoprost group and 20·1 mm Hg (4·8) in 258 controls. At 
24 months, mean reduction in intraocular pressure was 3·8 mm Hg (4·0) in 231 patients assessed in the latanoprost 
group and 0·9 mm Hg (3·8) in 230 patients assessed in the placebo group. Visual ﬁ eld preservation was signiﬁ cantly 
longer in the latanoprost group than in the placebo group: adjusted hazard ratio (HR) 0·44 (95% CI 0·28–0·69; 
p=0·0003). We noted 18 serious adverse events, none attributable to the study drug.
Interpretation This is the ﬁ rst randomised placebo-controlled trial to show preservation of the visual ﬁ eld with an 
intraocular-pressure-lowering drug in patients with open-angle glaucoma. The study design enabled signiﬁ cant 
diﬀ erences in vision to be assessed in a relatively short observation period.
Funding Pﬁ zer, UK National Institute for Health Research Biomedical Research Centre.
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Introduction
Open-angle glaucoma is a chronic progressive optic 
neuropathy that causes a loss of vision, predominantly 
aﬀ ecting the mid-peripheral visual ﬁ eld at ﬁ rst and later 
damaging central vision as the disease progresses; 
although increasingly evidence suggests unrecognised 
damage to central vision early in the disease course. 
Glaucomatous vision loss is associated with restricted 
mobility,1 falls and motor vehicle accidents,2 and is the 
leading cause of irreversible blindness worldwide and the 
second major cause for blind registration in the UK.3,4 The 
prevalence of open-angle glaucoma increases 
exponentially with age and the level of intraocular 
pressure.5 Drugs to reduce intraocular pressure have been 
used for decades to slow or halt progressive vision loss in 
patients with open-angle glaucoma, yet there has been no 
placebo-controlled trial to assess vision preservation with 
this treatment. For most patients, the ﬁ rst-choice drug is a 
prostaglandin analogue,6 although a recent Cochrane 
review of medical interventions for glaucoma reported no 
published evidence for a protective eﬀ ect on vision.7 The 
United Kingdom Glaucoma Treatment Study (UKGTS) is 
the ﬁ rst placebo-controlled trial to assess the eﬀ ect of 
intraocular-lowering treatment on vision preservation.
Previous trials to assess intraocular-lowering treatment 
on vision preservation in open-angle glaucoma have 
compared medical treatment with no treatment,8 combined 
medical and laser therapy with no treatment (the Early 
Manifest Glaucoma Trial9 [EMGT] in 2002), one medical 
treatment with another,10,11 medical, laser, or surgical 
intraocular pressure reduction with no treatment,12 medical 
with laser and surgical pressure reduction,13 initial medical 
with surgical pressure reduction,14,15 and diﬀ erent laser and 
surgical sequences in addition to medical treatment (the 
Advanced Glaucoma Intervention Study16 [AGIS]). To our 
knowledge, no study has been done in patients with open-
Lancet 2015; 385: 1295–304
Published Online
December 19, 2014
http://dx.doi.org/10.1016/
S0140-6736(14)62111-5
This online publication has 
been corrected. The corrected 
version ﬁ rst appeared at 
thelancet.com on July 10, 2015
See Comment page 1264
National Institute for Health 
Research Biomedical Research 
Centre at Moorﬁelds Eye 
Hospital NHS Foundation Trust 
and UCL Institute of 
Ophthalmology, London, UK 
(Prof D F Garway-Heath MD, 
C Bunce DSc, G Lascaratos MSc, 
F Amalﬁ tano BSc, T A Ho PhD, 
Krishna Patel MSc, 
R A Russell PhD, 
A Shah MRCOphth, K Suzuki PhD, 
E T White BSc, 
R P Wormald FRCOphth, 
W Xing MSc); Department of 
Optometry and Visual Science, 
City University, London, UK 
(Prof D P Crabb PhD, R A Russell); 
Huddersﬁ eld Royal Inﬁ rmary, 
Huddersﬁ eld, UK (N Anand MD); 
Aberdeen Royal Inﬁ rmary, 
Aberdeen, UK 
(Prof A Azuara-Blanco PhD); 
Hinchingbrooke Hospital, 
Huntingdon, UK 
(Prof R R Bourne MD); Norfolk 
and Norwich University 
Hospital, Norfolk, UK 
(D C Broadway MD); 
Birmingham Heartlands and 
Solihull, Birmingham, UK 
(I A Cunliﬀ e FRCOphth, 
A Negi MD); Bristol Eye 
Hospital, Bristol, UK 
(J P Diamond PhD, 
Paul G Spry PhD); Sunderland 
Eye Inﬁ rmary, Sunderland, UK 
(S G Fraser MD); Addenbrooke’s 
Hospital, Cambridge, UK 
(Prof K R Martin DM); 
Cheltenham General Hospital, 
Cheltenham, UK 
(A I McNaught MD); and 
University Hospitals Leuven, 
Leuven, Belgium 
(Prof T G Zeyen PhD)
Correspondence to:
Articles
1296 www.thelancet.com   Vol 385   April 4, 2015
Prof David F Garway-Heath, 
Moorﬁ elds Eye Hospital, London 
EC1V 2PD, UK
david.garway-heath@
moorﬁ elds.nhs.uk
angle glaucoma to assess the vision-preserving eﬃ  cacy of 
one drug in a placebo-controlled trial.
The observation period for trials of visual ﬁ eld 
preservation in patients with open-angle glaucoma has 
typically been 5 years or longer,9,12,15,16 with the shortest trial 
lasting 30 months.11 Long trial duration hinders the 
assessment of new interventions to prevent vision loss 
and increases the cost of drug development, which, in 
turn, reduces the likelihood of new treatments being 
made available for patient beneﬁ t. Therefore, the design 
of UKGTS incorporated approaches for the measurement 
of outcomes that have potential to shorten study design, 
including repeated tests on visits (clustering) at the 
beginning and end of the observation period and imaging 
the retinal nerve ﬁ bre layer and optic nerve head. Both the 
clustering and inclusion of imaging can increase the 
precision of estimates of the rate (speed) of change.17,18 We 
aimed to assess the eﬀ ect of the prostaglandin analogue 
latanoprost on the visual ﬁ eld preservation of patients 
with open-angle glaucoma in a comparatively short trial.
Methods
Study design and participants
The UKGTS is a randomised, multicentre, triple-masked, 
parallel-group, placebo-controlled trial, undertaken in ten 
participating centres (tertiary referral centres, teaching 
hospitals, and district general hospitals) throughout 
the UK. The study design and baseline characteristics of 
UKGTS participants have been published previously.19,20
We consecutively identiﬁ ed participants with newly 
diagnosed, untreated open-angle glaucoma. Our eligibility 
criteria were closely modelled on those from the EMGT21 
to allow comparison and meta-analysis. Open-angle 
glaucoma was deﬁ ned as the presence of glaucomatous 
visual ﬁ eld defects in at least one eye with corresponding 
damage to the optic nerve head (see supplemental 
procedures in the appendix) and an open iridocorneal 
drainage angle on gonioscopy. We allowed patients with 
primary open-angle glaucoma and pseudoexfoliation 
glaucoma, but not pigment dispersion glaucoma. 
Exclusion criteria included advanced glaucoma (visual 
ﬁ eld mean deviation worse than –10 dB in the better eye 
or –16 dB in the worse eye), mean baseline intraocular 
pressure of 30 mm Hg or higher, Snellen visual acuity 
worse than 6/12, and poor image quality (>40 μm mean 
pixel height standard deviation) with the Heidelberg 
retina tomograph (Heidelberg Engineering, Heidelberg, 
Germany). After the Moorﬁ elds Eye Hospital Reading 
Centre conﬁ rmed eligibility and the patient gave informed 
consent, the Moorﬁ elds Clinical Trials Unit assigned a 
study identiﬁ cation number.
The study was undertaken in accordance with good 
clinical practice guidelines and adhered to the Declaration 
of Helsinki. The trial was approved by the Moorﬁ elds and 
Whittington Research Ethics Committee on June 1, 2006 
(reference 09/H0721/56). All patients provided written 
informed consent before screening investigations. An 
independent Data and Safety Monitoring Committee 
(DSMC) was appointed by the trial steering committee. 
The trial manager monitored adverse events, which were 
reported immediately to the operational DSMC at 
Moorﬁ elds Eye Hospital. Serious adverse events were 
reported to the Medicines and Healthcare Products 
Regulatory Agency.
Randomisation and masking
We randomly allocated participants (1:1) to either 
latanoprost 0·005% or latanoprost vehicle eye drops 
(placebo) alone once a day in both eyes. Patients were 
enrolled by clinicians at each site; once eligibility was 
conﬁ rmed by the reading centre, the Moorﬁ elds Clinical 
Trials Unit assigned patients the next available study 
identiﬁ cation number. We did randomisation in 
permuted blocks of varying sizes (block sizes range from 
4 to 10), stratiﬁ ed by participating centre. The random-
isation schedule, drawn up by the research and 
development statisticians at Moorﬁ elds Eye Hospital on a 
randomisation website, was sent to the Pharmaceutical 
Manufacturing Unit, which labelled the bottles with the 
participant study identiﬁ cation number only. Latanoprost 
and placebo eye drops were provided in identical-looking 
bottles. Participants, clinicians, and assessors of the 
primary outcome were masked to the treatment 
allocation and clinicians were encouraged not to tell the 
participants their intraocular pressure measurements.
Outcomes
After the funding decision and before trial initiation, the 
primary endpoint was changed from the one used in the 
EMGT—at least three test locations showing signiﬁ cant 
deterioration at the p<0·05 level in three consecutive 
30–2 visual ﬁ elds—to at least three visual ﬁ eld locations 
worse than baseline at the 5% levels in two consecutive 
reliable visual ﬁ elds and at least three visual ﬁ eld 
locations worse than baseline at the 5% levels in the two 
subsequent consecutive reliable visual ﬁ elds; the 
locations identiﬁ ed in the ﬁ rst and second pair were not 
required to be identical. This change was made because 
the visual ﬁ eld test in the UKGTS was smaller in extent 
(24–2), and therefore fewer locations were tested than in 
the EMGT. Time to progression was deﬁ ned as time 
from baseline to the fourth visual ﬁ eld that conﬁ rmed 
progression. The primary endpoint was assessed on the 
day of each visit and then veriﬁ ed by the Reading Centre.
After the publication of the National Institute for 
Health and Care Excellence Guideline Diagnosis and 
Management of Chronic Open Angle Glaucoma and Ocular 
Hypertension,6 the independent DSMC requested an 
(unplanned) interim analysis on Jan 6, 2011, based on 
time-to-event. The Steering Committee therefore 
formally adopted time-to-event for the primary outcome. 
On the basis of the interim analysis, the DSMC requested 
an early termination of the trial and patients were 
scheduled for exit visits over the subsequent 3 months. 
See Online for appendix
For the randomisation 
website see http://www.
randomization.com
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We give survival data of diﬀ erences in time from baseline 
to the event of conﬁ rmed deterioration between treatment 
groups. Additional endpoints were intraocular pressure 
higher than 35 mm Hg on two successive occasions (safety 
endpoint) and visual acuity reduction to less than 6/18 
(non-glaucomatous vision change endpoint). We also 
report the original primary endpoint—proportion of 
patients with deterioration at 24 months in each group. 
Secondary outcomes included visual ﬁ eld deterioration 
rate (speed), measurements from imaging of the retinal 
nerve ﬁ bre layer and optic nerve head, and scores 
from patient-related outcome measures questionnaires at 
24 months, or at the time of a trial endpoint.19
Because visual ﬁ eld deterioration is more likely at 
higher intraocular pressures, patients leaving the trial 
after an endpoint would cause the mean intraocular 
pressure of those remaining to reduce over time. 
Therefore, missing data (from patients having reached 
an endpoint or being lost to follow-up) were imputed 
with the last observation carried forward (LOCF) method.
Procedures
We did visual ﬁ eld testing, intraocular pressure 
measurement, and imaging at 11 scheduled visits over 
24 months, with clustering of the tests at baseline, 
18 months, and 24 months; 16 visual ﬁ elds test were 
scheduled over 24 months. We measured vision function 
through testing of the visual ﬁ eld. The visual ﬁ eld test 
estimates retinal sensitivity, measured in dB, at 
54 locations across the central 24 degrees, one eye at a 
time; 52 of which are analysed in the instrument software 
for change over time. A summary measure of vision 
function is the average loss at all locations: the mean 
deviation. Criteria for incident damage are based on 
identiﬁ cation of visual ﬁ eld locations that are repeatedly 
worse than baseline; these criteria are sensitive and 
identify change before it is noticed by the patient. Visual 
ﬁ eld testing was done with the Humphrey Field Analyser 
Mark II (or II-i) with the Swedish interactive threshold 
algorithm standard 24–2 programme (Carl Zeiss Meditec, 
Dublin, CA, USA). We measured visual ﬁ eld deterioration 
with the Humphrey Field Analyzer II-i Guided Progression 
Analysis software (version 5.1.1). Two independent 
glaucoma-fellowship-trained ophthalmologists (Nick 
Strouthidis [Moorﬁ elds Eye Hospital] and Paul Foster 
[UCL]) conﬁ rmed that the deterioration was consistent 
with open-angle glaucoma on review of the visual ﬁ elds 
and a fundus photograph taken at the time that the patient 
reached the endpoint. For eye-related variables, the values 
for the eye with worse baseline mean deviations were 
taken. Detail of other procedures is given in the appendix.
Statistical analysis
At the start of the trial, we decided the sample size based 
on our outcome at 18 months. However, because 
recruitment was slower than we expected, we recalculated 
the sample size in Oct 8, 2008, for an outcome at 
24 months. We further revised the sample size in 
June 3, 2009, because of a greater than anticipated attrition 
rate. We established the ﬁ nal sample size (516 participants) 
to have 90% power with a two-sided error (α=0·05) to 
detect a diﬀ erence between 24% and 11% in incident 
visual ﬁ eld deterioration in 24 months’ follow-up, allowing 
for a 25% loss to follow-up over the study period.
We analysed all patients in the treatment group to which 
they were randomly assigned with all available data up to 
the point of withdrawal. If no data were available for any 
post-baseline assessment, we excluded patients from the 
analysis. We censored data from patients undergoing any 
ocular surgery at the last visit before surgery and included 
these patients in the loss to follow-up numbers.
We used survival analysis to compare the diﬀ erences in 
time from baseline to the event of conﬁ rmed deterioration 
between treatment groups. We estimated treatment 
eﬀ ect as hazard ratios (HR) with 95% CIs computed by a 
Cox proportional hazards model that included terms, 
prespeciﬁ ed in the statistical analysis plan, for treatment, 
baseline covariates (age at baseline, race [white or 
non-white], sex, baseline intraocular pressure, baseline 
mean deviation, blood pressure, refractive error, axial 
length, and central corneal thickness), and study centre. 
For patients who had no post-baseline data, we developed 
a regression model with the remaining data and used 
Figure 1: Study proﬁ le
IOP=intraocular pressure. VF=visual ﬁ eld. Four patients who did not fulﬁ l the eligibility criteria were randomised. 
Two did not attend any post-baseline visits (both in the latanoprost group). Of the remaining two, one was 
analysed in the latanoprost group and one in the placebo group.
777 patients assessed for eligibility 
516 enrolled 
261 excluded because did not meet 
 inclusion criteria or declined to 
 participate
258 randomly allocated to placebo 
230 analysed, including participants 
  with <21 months’ follow-up
 39 did not attend all follow-up
 1 reached IOP endpoint 
 5 completed 18 months’ follow-up 
  before trial extension 
 35 had incomplete follow-up 
  because the trial was terminated
  early
 1 did not meet eligibility criteria
231 analysed, including participants 
  with <21 months’ follow-up
 32 did not attend all follow-up
 7 completed 18 months’ follow-up 
  before trial extension 
 31 had incomplete follow-up 
  because the trial was terminated
  early
 1 VF endpoint suspected to be 
  non-glaucomatous
 1 did not meet eligibility criteria
258 allocated to latanoprost 
28 did not attend any post-baseline 
 study visits, including 3 reaching
 the IOP endpoint
27 did not attend any post-baseline 
 study visits, including 2 who did
 not meet trial eligibility criteria
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this to estimate times to progression. The Cox model was 
re-run with the imputed values for the patients with no 
post-baseline data and estimates compared with the 
available case model.
We investigated reasons for loss to follow-up with 
logistical regression of covariates (including treatment 
group, intraocular pressure, baseline mean deviation, 
age, sex, and ethnic origin) on an indicator of loss. 
Summary measurements for continuous, normally 
distributed, outcome values were diﬀ erences in means 
and corresponding 95% CIs. For non-parametric 
equivalents, we used non-normally distributed outcome 
measures. For categorical variables, we used a 
Pearson’s χ² or Fisher’s exact test. We used survival 
analysis and linear regression to assess glaucoma severity 
as a risk for visual ﬁ eld deterioration. We used linear 
regression to assess imaging outcomes for evidence of 
deterioration before a conﬁ rmed visual ﬁ eld endpoint in 
patients with baseline mean deviation lower than –10 dB 
(appendix). All statistical tests used a two-sided p value of 
0·05. We did statistical analyses with Stata (version 12). 
This trial is registered, number ISRCTN96423140.
Role of the funding source
The funders had no input into the design, conduct, data 
collection, analysis, result interpretation, or reporting of 
the study. Some of the authors are employed by the 
sponsor organisation (Moorﬁ elds Eye Hospital). The 
organisation itself had no input. The corresponding 
author has full access to all data and had ﬁ nal 
responsibility to submit for publication.
Placebo group 
(n=258)
Latanoprost 
group 
(n=258)
Centre
Moorﬁ elds Eye Hospital 45 (17%) 46 (18%)
Aberdeen Royal Inﬁ rmary 21 (8%) 21 (8%)
Norfolk and Norwich University Hospital 42 (16%) 41 (16%)
Birmingham Heartlands and Solihull 37 (14%) 37 (14%)
Cheltenham General Hospital 12 (5%) 12 (5%)
Bristol Eye Hospital 13 (5%) 13 (5%)
Sunderland Eye Inﬁ rmary 16 (6%) 16 (6%)
Hinchingbrooke Hospital 55 (21%) 54 (21%)
Addenbrooke’s Hospital 10 (4%) 11 (4%)
West of England Eye Unit 1 (<1%) 1 (<1%)
Huddersﬁ eld Royal Inﬁ rmary 6 (2%) 6 (2%)
Family history of glaucoma
None 175 (68%) 173 (67%)
First–degree relative 82 (32%) 82 (32%)
Other family history 1 (<1%) 1 (<1%)
Unknown 0 2 (1%)
Age (years)
Mean 66 (10) 65 (11)
20–29 1 (<1%) 1 (<1%)
30–39 2 (1%) 2 (1%)
40–49 17 (7%) 23 (9%)
50–59 56 (22%) 41 (16%)
60–69 80 (31%) 101 (40%)
70–79 84 (33%) 78 (30%)
≥80 18 (7%) 12 (5%)
Sex
Female 125 (48%) 118 (46%)
Male 133 (52%) 140 (54%)
Education level
Degree 46 (18%) 50 (19%)
Apprenticeship or certiﬁ cate 70 (27%) 67 (26%)
Ended at age 18 years 13 (5%) 20 (8%)
Ended at age 16 years 126 (49%) 118 (46%)
Unknown 3 (1%) 3 (1%)
(Table 1 continues in next column)
Placebo group 
(n=258)
Latanoprost 
group 
(n=258)
(Continued from previous column)
Ethnic origin
White 230 (89%) 235 (91%)
Black 17 (7%) 10 (4%)
Asian 7 (3%) 9 (4%)
Other 1 (<1%) 2 (<1%)
Unknown 3 (1%) 2 (<1%)
Systolic blood pressure
Mean (mm Hg) 135·7 (20·2) 135·5 (19·4)
Missing data* 22 (9%) 21 (8%)
Diastolic blood pressure
Mean (mm Hg) 80·3 (11·0) 81·1 (10·5)
Missing data* 22 (9%) 21 (8%)
Hypertension
Receiving treatment 102 (40%) 105 (41%)
Manifest hypertension 
(BP>140/90 mm Hg)
118 (46%) 110 (43%)
Medical history
Heart attack 15 (6%) 13 (5%)
Bronchitis or emphysema 15 (6%) 16 (6%)
Asthma or wheezing 30 (12%) 30 (12%)
General arteriosclerosis (stroke, angina, 
and claudication)
13 (5%) 25 (10%)
Diabetes 25 (10%) 29 (11%)
Concomitant neurological disease 
(Parkinson’s disease, Alzheimer’s disease, 
multiple sclerosis, or deafness)
32 (12%) 33 (13%)
Migraine 50 (19%) 51 (20%)
Peripheral vasospasm 94 (36%) 88 (34%)
Medication use
Corticosteroids (including inhalers) 17 (7%) 28 (11%)
Statins 65 (25%) 75 (29%)
Other 157 (61%) 151 (59%)
Data are n (%) or mean (SD). BP=blood pressure. *Data are missing for 
participants who did not attend the ﬁ rst post–allocation visit.
Table 1: Baseline characteristics
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Results
Between Dec 1, 2006, and March 16, 2010, we enrolled 
516 patients (ﬁ rst randomisation Feb 1, 2007; ﬁ gure 1). 
55 patients did not attend any post-baseline visits (27 from 
the latanoprost group and 28 from the placebo group) 
and, therefore, provided no outcome data to analyse. Four 
patients were found to not fulﬁ l eligibility criteria after 
randomisation, but the two with post-baseline data were 
included in the analysis. We analysed data for the primary 
trial outcome for 461 patients (ﬁ gure 1). 
Table 1 shows baseline characteristics of participants and 
table 2 shows eye-related parameters. Treatment groups 
were mostly similar; arteriosclerosis was more common in 
patients given latanoprost than in controls (table 1). Mean 
intraocular pressure at baseline seemed slightly higher in 
the placebo group than in the latanoprost group (table 1).
Within 24 months, 94 participants had visual ﬁ eld 
deterioration consistent with glaucomatous progression 
in 461 patients with post-baseline data (231 in the 
Placebo group 
(n=258)
Latanoprost group 
(n=258)
Eyes eligible for trial
Both eyes 136 (53%) 129 (50%)
Right eye only 62 (24%) 68 (26%)
Left eye only 59 (233%) 58 (22%)
Neither 1 (<1%) 3 (1%)
Refractive error
Mean (D) –0·7 (3·1) –0·7 (3%)
Less than –1 D 80 (31%) 87 (34%)
–1 to 1 D 118 (46%) 110 (43%)
More than 1 D 60 (23%) 60 (23%)
Unknown 0 1 (<1%)
Best-corrected visual acuity
Mean 0·95 (0·24) 0·94 (0·22)
0·5 to 0·6 91 (36%) 81 (31%)
1·0 and better 165 (64%) 177 (69%)
Missing data* 2 (1%) 0
Axial length
Mean (mm) 24·1 (1·27) 24·1 (1·31)
Missing data* 31 (12%) 29 (11%)
CCT
Mean (mm) 543·6 (33·3) 539·3 (33·9)
Missing data* 27 (11%) 25 (10%)
SAP MD
Better eye
Mean (dB) –1·6 (1·9) –1·4 (1·9)
Median (dB) –1·4 (–2·6 to –1·3) –1·2 (–2·1 to –0·1)
Worse eye
Mean (dB) –4·4 (3·4) –4·3 (3·4)
Median (dB) –3·3 (–6·0 to –2·0) –3·3 (–5·3 to –2·1)
GAT IOP, mm Hg
Mean 20·1 (4·8) 19·6 (4·6)
<15 29 (11%) 36 (14%)
15–19 102 (40%) 107 (42%)
20–24 83 (32%) 80 (31%)
25–29 37 (14%) 29 (11%)
≥30 7 (3%) 6 (2%)
Any iridotrabecular contact
Yes 25 (10%) 22 (9%)
No 232 (90%) 236 (92%)
Unknown 1 (<1%) 0
(Table 2 continues in next column)
Placebo group 
(n=258)
Latanoprost group 
(n=258)
(Continued from previous column)
Van Herick grade
0% 2 (1%) 3 (1%)
≥5% 0 1 (<1%)
≥15% 7 (3%) 7 (3%)
≥25% 64 (25%) 47 (18%)
≥40% 185 (72%) 200 (78%)
Unknown 6 (2%) 8 (3%)
Any peripheral anterior synechiae
Yes 2 (1%) 1 (1%)
No 254 (98%) 257 (99%)
Unknown 2 (1%) 0
Trabecular pigment density
0 48 (19%) 45 (17%)
1 156 (61%) 158 (61%)
2 45 (17%) 45 (17%)
3 5 (2%) 10 (4%)
Unknown 4 (2%) 0
Pseudoexfoliation
0 250 (97%) 255 (99%)
1 0 1 (<1%)
2 1 (<1%) 0
Unknown 7 (3%) 2 (1%)
LOCS lens grading–N
N ≥1 139 (54%) 137 (54%)
N <1 113 (44%) 118 (46%)
Unknown 6 (2%) 3 (1%)
LOCS lens grading–C
C ≥2 12 (5%) 10 (3·8)
C <2 240 (93%) 245 (95·0)
Unknown 6 (2%) 3 (1·2)
LOCS lens grading–P
P ≥1 20 (8%) 21 (8%)
P <1 232 (90%) 234 (91%)
Unknown 6 (2%) 3 (1%)
Data are n (%) or mean (SD) and median (IQR). Values given are for pre-allocation 
or post-allocation visit 1. Where relevant, values for the eye with the worse visual 
ﬁ eld mean deviation are given. CCT=central corneal thickness. SAP MD=standard 
automated perimetry mean deviation. GAT IOP=Goldmann applanation tonometry 
intraocular pressure. D=dioptres. LOCS=lens opacity classiﬁ cation system. 
N=nuclear cataract. C=cortical cataract. P=posterior subcapsular cataract.*Data are 
missing for participants who did not attend the ﬁ rst post–allocation visit.
Table 2: Baseline characteristics of the latanoprost-treated versus 
placebo-treated eyes of patients
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latanoprost group and 230 in the placebo group). 
59 (25·6%; 95% CI 20·1–31·8) patients in the placebo 
group reached the deterioration endpoint at 24 months 
compared with 35 (15·2%; 10·8–20·4) in the latanoprost 
group (p=0·006). In one additional participant, an 
endpoint was deemed potentially to be due to a non-
glaucomatous process. The visual ﬁ eld deterioration 
endpoint was reached in both eyes of ten participants. 
Based on the 94 patients with visual ﬁ eld deterioration 
events during the 24 month observation period, time to 
ﬁ rst deterioration was signiﬁ cantly longer in the 
latanoprost group than in the placebo group (adjusted 
HR 0·44, 95% CI 0·28–0·69; p=0·0003; ﬁ gure 2). 
Treatment diﬀ erences were evident at 18 months (0·43; 
0·26–0·71; p=0·001), and 12 months (0·47; 0·23–0·95; 
p=0·035). 193 (75%) participants in the placebo group 
and 210 (81%) in the latanoprost group were taking trial 
drops and under observation or had reached an endpoint 
at 12 months. In the model with imputation, the primary 
endpoint HR was 0·43 (95% CI 0·26–0·69; p=0·0005).
At the ﬁ rst visit after treatment allocation, mean 
intraocular pressure reduction from baseline was 
5·0 mm Hg (SD 3·6) in the latanoprost group and 
1·4 mm Hg (3·1) in the placebo group. At 24 months, the 
mean intraocular pressure reduction from baseline was 
4·0 mm Hg (3·4) in the latanoprost group and 
1·3 mm Hg (3·6) in the placebo group (ﬁ gure 3A). After 
we applied the LOCF adjustment, the intraocular 
pressure reduction at 24 months from baseline was 
3·8 mm Hg (4·0) in the latanoprost group and 
0·9 mm Hg (3·8) in the placebo group (ﬁ gure 3B).
In participants reaching a visual ﬁ eld endpoint, the 
mean change in mean deviation was –1·6 dB (IQR –0·6 to 
–2·6 dB; ﬁ gure 4). Mean change in visual acuity (decimal) 
at last visit from baseline was +0·01 for eyes with visual 
ﬁ eld progression and –0·02 for eyes without visual ﬁ eld 
progression (Wilcoxon rank-sum test for diﬀ erence 
p=0·3). Change from baseline visual acuity was –0·01 in 
the placebo group and –0·02 in the latanoprost group 
(Wilcoxon rank-sum test for diﬀ erence p=0·9).
27 (10%) patients in the latanoprost group and 28 (11%) 
participants in the placebo group did not attend any 
post-baseline appointments. We explored the following 
associations for patients lost to follow-up (those with no 
post-baseline visits): age, sex, baseline intraocular pressure, 
baseline visual ﬁ eld loss, ethnic origin, and treatment 
group. There were no associations at the p<0·05 level.
A further 32 (12%) patients in the latanoprost group and 
39 (15%) in the placebo group had shorter than 21 months’ 
follow-up because of failure to attend follow-ups or they 
had an intraocular pressure endpoint (ﬁ gure 1). Of those Figure 2: Kaplan-Meier failure estimates for visual ﬁ eld progression
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lost by reason of ocular comorbidity, eight underwent 
cataract surgery (ﬁ ve from the placebo group), seven of 
which were within 7 months of the baseline visit (table 3, 
table 4). Of the 3750 scheduled appointments before 
planned trial exit or loss to follow-up, 63 (2%) were missed; 
32 by patients in the placebo group and 31 by those in the 
latanoprost group. 79 participants had incomplete follow-
up from early trial termination or had completed 
18 months’ follow-up before the extension of the 
observation period (ﬁ gure 1, appendix).
An intraocular pressure safety endpoint was reached in 
six participants, two of whom simultaneously reached a 
visual ﬁ eld endpoint. No patient reached a visual acuity 
reduction endpoint. 192 adverse events (99 in patients 
allocated to placebo and 93 in patients allocated to 
latanoprost) were reported in 98 participants (50 participants 
in the latanoprost group and 48 in the placebo group; 
table 3). 13 of 153 mild adverse events and one of 21 moderate 
adverse events were thought to be possibly related to study 
drugs (four in the placebo group, ten in the latanoprost 
group). 18 serious AEs were reported (nine in the placebo 
group and nine in the latanoprost group), none attributed to 
the study drug. Seven patients withdrew because of a 
possible adverse reaction to study drug (table 4): local allergy 
(in two patients), drop intolerance (in three), diarrhoea (in 
one), and asthma (in one).
Discussion
Systematic reviews of treatment for glaucoma have 
reported no placebo-controlled trials in patients with open-
angle glaucoma with visual function as the outcome 
(panel).9,23 To our knowledge, no evidence exists for a 
protective eﬀ ect on vision for the most frequently 
prescribed class of drugs to lower intraocular pressure—
prostaglandin analogues.7 To our knowledge, UKGTS is 
the ﬁ rst placebo-controlled trial to show visual ﬁ eld 
preservation through lowering of intraocular pressure 
with topical drugs in patients with open-angle 
glaucoma and to show the visual-ﬁ eld-preserving eﬀ ect of 
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end point
(A) Shows median (horizontal bar), IQR (shaded box), 1·5-times the IQR 
(whiskers), and outliers (open circles). (B) Scatterplot of baseline MD versus MD 
at endpoint. MD=mean deviation.
Placebo group (n=230) Latonoprost group (n=231)
Number of events n (%) Number of events n (%)
Mild
Total mild events 77 39 (17%) 76 40 (17%)
Ocular
Unscheduled drop holiday 2 2 (1%) 2 2 (1%)
Ocular discomfort* 14 14 (6%) 16 13 (6%)
Conjunctivitis† 6 6 (3%) 6 6 (3%)
Adnexal‡ 3 1 (<1%) 2 2 (1%)
Subconjunctival haemorrhage 2 2 (1%) 3 3 (1%)
Vision alteration§ 14 12 (5%) 11 8 (3%)
Optic disc haemorrhage 10 6 (3%) 7 6 (3%)
Non-ocular
General medical¶ 26 15 (7%) 29 22 (10%)
Moderate
Total moderate events 13 9 (4%) 8 8 (3%)
Ocular
Conjunctivitis 0 0 2 2 (1%)
Vision alteration 3 2 (1%) 2 2 (1%)
Non–ocular
General medical|| 10 7 (3%) 4 4 (2%)
Serious
Total serious events 9 7 (3%) 9 8 (3%)
Death (unknown cause) 0 0 2 2 (1%)
Cancer diagnosis 4 4 (2%) 2 2 (1%)
Cerebrovascular accident 1 1 (<1%) 4 3 (1%)
Myocardial infarction 2 2 (1%) 1 1 (<1%)
Other (surgery) 2 2 (1%) 0 0
 *Includes dry eyes and blepharitis. †Includes infective and allergic conjunctivitis. ‡Includes blocked nasolacrimal duct 
and eyelid papillae. §Includes cataract, age-related macular degeneration, and diabetic maculopathy. ¶General medical 
(mild) includes respiratory infection, injury, arthritis, and suspected cancer. ||General medical (moderate) includes 
inpatient surgery and other hospital admissions. 
 Table 3: Adverse events
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latanoprost, the drug most frequently used in high-income 
countries. Previous studies, such as the EMGT9 and the 
Collaborative Normal Tension Glaucoma Study,12 have 
assessed the outcome of combined treatments to lower 
intraocular pressure. Our placebo-controlled trial is of 
clinical relevance in view of the results of a recent trial by 
Krupin and colleagues suggesting very diﬀ erent vision-
preserving action of two drugs with similar intraocular-
pressure-lowering eﬃ  cacy.11 The eﬀ ect size in the UKGTS 
was large, with an adjusted HR of 0·44 (95% CI 0·28–0·69), 
associated with initial intraocular pressure-lowering of 
5·0 mm Hg (SD 3·6) in the latanoprost group and 
1·4 mm Hg (3·1) in the placebo group. The initial 
intraocular pressure reduction from baseline (5·0 mm Hg 
of 19·6 mm Hg; 26%) with latanoprost in our trial was 
lower than the 31% (peak) and 28% (trough) reduction 
from baseline reported in a meta-analysis by van der Valk 
and colleagues.24 However, in their meta-analysis, both the 
baseline peak (25·5 mm Hg) and trough (24·3 mm Hg) 
levels were higher than was the baseline pressure in the 
UKGTS (19·6 mm Hg). The intraocular pressure reduction 
at 24 months (3·8 mm Hg) is in line with data obtained for 
cohorts with lower baseline pressure—eg, 3·2 mm Hg 
from 17·6 mm Hg25 and 3·9 mm Hg from 18·8 mm Hg.26 
The reduction in intraocular pressure lessened a little over 
the 24 months; in the LOCF analysis, the intraocular-
pressure reduction compared with baseline was 
3·8 mm Hg in the latanoprost group and 0·9 mm Hg in 
the placebo group (ﬁ gure 3B). The pattern of intraocular-
pressure reduction, with a strong initial response that 
diminished after 6 months and then stabilised, has been 
reported previously.25 The pressure reduction in the 
placebo group (ﬁ gure 3B)—which was greater at the ﬁ rst 
post-allocation visit (1·4 mm Hg) than at the visit at 
24 months (0·9 mm Hg)—might be a regression-to-the-
mean eﬀ ect due to clinician behaviour (with the desire to 
recruit participants into a trial, a clinician might be more 
likely to accept borderline clinical ﬁ ndings as glaucoma 
when the intraocular pressure reading is high and, after 
randomisation and start of drops, might have a greater 
expectation of lower intraocular pressure at the ﬁ rst post-
allocation visit), or might be a true hypotensive eﬀ ect of 
latanoprost vehicle eye drops or a true placebo eﬀ ect.
Only two previous trials have been published of 
medical (non-incisional) treatment for open-angle 
glaucoma with an untreated control group and vision 
function as an outcome—the study by Holmin and 
colleagues8 and the EMGT.9 Neither study was placebo-
controlled or masked, although both had an objective 
(visual ﬁ eld) outcome. The study by Holmin and 
colleagues8 was very small (16 patients enrolled). Previous 
trials of open-angle glaucoma with visual ﬁ eld 
deterioration as an outcome have used widely diﬀ ering 
criteria to identify deterioration and have studied 
diﬀ ering clinical populations than each other,9,12,15,16 
whereas we chose the recruitment criteria and main 
outcome of the UKGTS to be similar to those of the 
EMGT to allow comparison and meta-analysis of results. 
The outcome criterion was established from the 
glaucoma change probability maps, which are based on 
the pattern deviation, limiting the eﬀ ect of homogeneous 
reduction in diﬀ erential light sensitivity seen with 
cataract.9 The observation period of the trial was short 
(24 months) and little change in lens opacity would be 
expected; as shown by the stability of the visual acuity 
over the duration of this study.
From our estimation of incident progression from the 
survival curves (ﬁ gure 2), a visual ﬁ eld endpoint was 
reached by 24 months in 34% of participants in the 
untreated group of the UKGTS and 25% in the untreated 
group of the EMGT, versus in 20% of participants in the 
Latanoprost 
group (n=58)
Placebo group 
(n=69)
Adverse reaction to study drug 4 (3%) 3 (2%)
Ill health 10 (8%) 22 (17%)
Death 5 (4%) 2 (2%)
Ocular comorbidity* 6 (5%) 5 (4%)
Intraocular pressure endpoint 0 (0%) 4 (3%)
Unknown or other 33 (26%) 33 (26%)
Data are n (% of those with less than 21 months follow-up; total 127). *Included 
cataract, angle closure, or uveitis.
Table 4: Reasons for follow-up of less than 21 months
Panel: Research in context
Systematic review
On Nov 10, 2013, we searched the Cochrane Eyes and Vision database with the subtopics 
Glaucoma–Glaucoma, open angle–Treatment–Topical therapy. The search identiﬁ ed two 
relevant reviews about medical treatment for open-angle glaucoma,7,22 but no placebo-
controlled trials assessing the beneﬁ t of topical intraocular pressure-lowering drugs on 
preservation of visual function. Notably, no evidence was available for the vision-
preserving eﬀ ects of intraocular pressure-lowering by prostaglandin analogues—the most 
commonly-prescribed class of drug for glaucoma. We searched PubMed for papers 
published from May 1, 2007, to Nov 10, 2013, with the MeSH terms “glaucoma”, “clinical 
trial”, and “visual ﬁ eld”. This search identiﬁ ed 76 publications, including one additional 
open-label medical treatment study10 with vision function as a primary outcome that was 
not already identiﬁ ed in the Cochrane reviews. We assessed trial quality on the basis of 
four metrics: allocation concealment, performance bias, detection bias, and attrition bias.
Interpretation
To our knowledge, the United Kingdom Glaucoma Treatment Study (UKGTS) is the ﬁ rst 
randomised, triple-masked, placebo-controlled trial to assess the beneﬁ t of topical 
medical treatment (eye drops) for reduction of loss of vision in patients with open-angle 
glaucoma. Our ﬁ ndings provide strong evidence for the vision-preserving beneﬁ t of 
lowering of intraocular pressure, supporting evidence from previous randomised trials 
that were not masked or placebo-controlled. The study also provides evidence of the 
vision-preserving beneﬁ ts of topical prostaglandin analogues. The trial design meant a 
fairly short observation period was needed to show treatment eﬀ ects on vision, with the 
diﬀ erence between treatment groups evident at just 12 months compared with typical 
observation periods of roughly 5 years in previous trials. The short trial duration will have 
a major beneﬁ cial eﬀ ect on development and assessment of new treatments, increasing 
the likelihood of these treatments being made available for patient beneﬁ t.
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treated group of the UKGTS and 11% in the treated group 
of the EMGT. Since baseline intraocular pressure 
(19·9 mm Hg in UKGTS, 20·6 mm Hg in EMGT) and 
participant age (66 years in UKGTS, 68 years in EMGT) 
were similar,20,21 the higher incident progression in the 
UKGTS might have been caused by the more sensitive 
criterion to identify progression. The relative sensitivity 
of the endpoint criteria can be judged from the median 
change in visual ﬁ eld mean deviation between baseline 
examination and the time at which deterioration was 
conﬁ rmed: –1·6 dB for the UKGTS criterion (ﬁ gure 4) 
and –1·9 dB for the EMGT criterion.27 Incident 
progression was reduced by 41% in the treated group of 
UKGTS, compared with a 58% reduction in the EMGT; 
this ﬁ nding is consistent with the 16% smaller intraocular 
pressure-lowering treatment eﬀ ect in the UKGTS 
(–3·8 mm Hg vs –4·5 mm Hg in the EMGT).
Strengths of the UKGTS trial (and EMGT trial) are that 
newly diagnosed, previously untreated participants were 
studied, so that the results are free of inﬂ uence from 
previous therapeutic interventions and the natural 
history of open-angle glaucoma can be studied in the 
untreated patients. Because consecutive new patients 
were assessed and recruited for the UKGTS trial, the 
population studied was representative of the target 
population considered for treatment and on which the 
trial results will be applied.
The UKGTS has the shortest observation period of any 
glaucoma trial with a vision function outcome,9–13,15,16 with 
a statistically signiﬁ cant diﬀ erence between treatment 
groups evident at only 12 months, as well as at the 
planned 24 month analysis timepoint. However, because 
the signiﬁ cance of the diﬀ erence in proportions surviving 
in the EMGT was p=0·004 after 48 months’ observation,9 
the diﬀ erence between treatment groups in the EMGT 
was probably signiﬁ cant over a much shorter observation 
period than was reported. The short observation period 
needed to observe a treatment eﬀ ect can bring many 
beneﬁ ts, speeding up novel drug development with 
consequent cost reduction and thereby increasing the 
likelihood of bringing new drugs to patients. The short 
observation period was achieved by adopting a sensitive 
change-from-baseline event criterion to identify visual 
ﬁ eld deterioration, frequent visual ﬁ eld tests, and a 
suﬃ  ciently large sample size. Also, the UKGTS design 
included additional features that might further reduce 
study duration and sample size. We aimed to improve 
the accuracy and precision of the rate (speed) of 
progression by including the clustering of tests at the 
beginning and end of the observation period17 and 
quantitative imaging of the retinal nerve ﬁ bre layer and 
optic nerve head;18 the analysis of these secondary 
outcomes will be reported elsewhere.
Because two-thirds of patients in the placebo group had 
no detectable deterioration within 24 months, and the 
small amount of change needed for an endpoint occurred 
in just one eye of almost 90% of participants with data, the 
questions arises as to whether some patients with 
glaucoma, particularly those with less visual ﬁ eld loss at 
baseline and those at lower risk of progression,28,29 could 
be monitored without treatment for a period. Investigators 
have previously suggested initial careful observation 
without treatment in patients with open-angle glaucoma9 
and normal tension glaucoma.30 Because deterioration 
patterns are diﬃ  cult to predict,31 an observation period 
would be advantageous to identify patients who might not 
need treatment, thereby avoiding the unnecessary burden 
of treatment for such patients. The rate of progression of 
visual ﬁ eld loss might change over extended observation 
periods, and so regular reassessments of the rate of 
progression would be advisable.
A potential limitation of the UKGTS was the relatively 
high loss to (or incomplete) follow-up, which can reduce 
the generalisability of the results. However, individuals 
lost to follow-up were generally similar to those remaining 
in the trial. In addition, participant ascer tainment was not 
population-based, but based on referral from primary 
care (community optometry practice); however, the 
participant characteristics in the UKGTS20 were strikingly 
similar to those in the EMGT, in which ascertainment 
was largely based on population screening.21 UKGTS 
participants were predominantly white (about 90%), 
which might also reduce gen eralisability of our ﬁ ndings 
to some subpopulations in the UK or other countries who 
might exhibit greater susceptibility to vision loss.32,33 
Furthermore, individuals with advanced open-angle 
glaucoma were excluded so that the results of the trial 
only apply to patients with mild to moderate glaucoma. 
Subsequent publications will address the eﬀ ect of 
treatment with respect to baseline intraocular pressure, 
glaucoma stage, participant age, and other risk factors.
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